Activated checkpoint kinase 2 expression and risk for oral squamous cell carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 12, 2007, Pages 2768-2772

  Yoon, Angela J ^a,c   Shen, Jing ^b   Santella, Regina M ^b   Zegarelli, David J ^a   Chen, Rongzhen ^c   Weinstein, I B ^c  

^a Division of Oral and Maxillofacial Pathology

^b Department of Environmental Health Sciences ^*

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHECKPOINT KINASE 2;

ACCURACY; AGED; ARTICLE; BIOPSY; CANCER GROWTH; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROPLASIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROTEIN-SERINE-THREONINE KINASES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 38849152763     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0659     Document Type: Article

References (12)

1. Cardesa AN, Gale N, Nadal A, Zidar N. Tumors of the Oral Cavity and Oropharynx. In: Barnes L, Eveson JW, Reichar P, Sidransky D, editors. World Health Organization Classification of Tumours, Pathology and Genetics of Head and Neck Tumors. Lyon (France): IARC Press; 2005. p. 118-81.
2. Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980;8:283-333.
3. Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer 1975;36:1386-92.
4. Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: a 20-year population-based perspective of malignant transformation. Oral Dis 2001;7:18-24.
5. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
6. Gorgoulis VG, Vassiliou LF, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
7. Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005;11:2855-72.
8. Ahn, J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair 2004;3:1039-47.
9. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54:150-80.
10. Mignogna MD, Fedele S, Russo LL, Muzio LL, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 2004;40:120-30.
11. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological and molecular biological characteristics. Crit Rev Oral Biol Med 2003;14:47-62.
12. Dakubo AD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.